Marsha Harris is a self-described fitness junkie &ndash; she loves staying active and can regularly be found at a ballet barre class or out on the golf course. So when she started experiencing labored breathing doing normal activities, she thought perhaps it was lingering effects of a respiratory virus. &ldquo;I was literally huffing and puffing and that wasn&rsquo;t normal,&rdquo; Marsha recalled. In February 2016, she decided to go to the doctor. Imaging tests confirmed lung cancer. When her doctor asked her where she&rsquo;d like to go for treatment, she immediately said the OSUCCC &ndash; James. There, she was referred to David Carbone, MD, PhD, head of thoracic oncology where she ultimately learned she had stage 4 lung adenonocarcinoma. Genomic testing revealed an EGFR mutation, which was highly treatable with a daily medication called afatinib (marketed as Gilotrif). The Food and Drug Administration approved the drug in 2013 as a first-line treatment in EGFR+ non-small cell lung cancers. She began treatment on March 12, 2016 &ndash; a day emblazoned in her memory &ndash; and her cancer has responded since. &ldquo;I have watched other people go through this disease and have very different outcomes. I feel good. I have energy. I can do what I want and live my life and I am so thankful for that opportunity,&rdquo; she says. To learn more about the lung cancer treatment team or clinical trials at The James, visit cancer.osu.edu/lungcancer or call 1-800-293-5066. New Research: Rise in Lung Adenocarcinoma Linked to Light Cigarettes A new study, published May 22, 2017, in the Journal of the National Cancer Institute (JNCI) shows that so-called &ldquo;light&rdquo; cigarettes have no health benefits to smokers and have likely contributed to the rise of a certain form of lung cancer that occurs deep in the lungs. OSUCCC &ndash; James researchers partnered with five other cancer centers to conduct a comprehensive multi-faceted analysis of existing literature that&nbsp;included chemistry and toxicology studies, human clinical trials and epidemiological studies of both smoking behavior and cancer risk. They studied scientific publications in the peer-reviewed literature and internal tobacco company documents. Results confirmed what public health experts have suspected for years: There is not health benefit to high-ventilation (light) cigarettes, long marketed by the tobacco industry as a &ldquo;healthier&rdquo; option &ndash; and those cigarettes are likely causing higher incidence rates of lung adenocarcinoma. Read more about this research.